Cat. #161710
Catalytically-inactive-JMJD6 U2OS cell line
Cat. #: 161710
Sub-type: Continuous
Organism: Human
Tissue: Bone
Disease: Myasthenic Syndrome
Model: Knock-Out; Knock-In
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Yvan Canitrot
Institute: Toulouse Tech Transfer
Primary Citation: Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Catalytically-inactive-JMJD6 U2OS cell line
- Alternate name: JMJD6 KO+Mut
- Cancer: Sarcoma
- Research fields: Cancer
- Tool sub type: Continuous
- Parental cell: U2OS
- Organism: Human
- Gender: Female
- Tissue: Bone
- Disease: Myasthenic Syndrome
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Knock-Out; Knock-In
- Model description: JMJD6 knock out using CRISPR-Cas9 and knock in of a catalytically inactive form of JMJD6
- Crispr: Yes
- Conditional: No
- Receptors of note: Insulin like growth factor
- Description: Catalitically inactive JMJD6 U2OS cell line used to study the role of the JMJD6 enzyme in DNA maintenance following DNA damage
- Application: Western blot, Immunofluorescence
- Production details: Gene inactivation by CRISPR-Cas9 and reintroduction of a mutant form of JMJD6 defective for its catalytic activity. Stable expression via a plasmid coding for JMJD6 mutant (H187A-D189A-H273A).
- Biosafety level: 1
- Recommended controls: Parental U2OS cell line, JMJD6 WT cell lines, JMJD6 deficient U2OS cell line
Target Details
- Target: Catalytically inactive JMJD6
- Target background: JMJD6 is an enzyme with intrinsic tyrosin kinase activity involved in the hydroxylation and de-methylation of histone and non-histone peptides with implications in the epigenetic changes of cancer. The jmjd6 gene also regulates its own splicing with the production of alternative splicied isoforms with different nuclear targets.
Applications
- Application: Western blot, Immunofluorescence
Handling
- Growth medium: DMEM medium supplemented with 10% foetal calf serum, sodium pyruvate and antibiotics (penicillin/streptomycin)
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: Penicillin, Streptomycin
Related Tools
- Related tools: JMJD6 deficient U2OS cell line, V5-tagged form of JMJD6 U2OS cell line
References
- Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339.
